On September 6, 2022 NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that compassionate use cases of SNK01 + an immune checkpoint inhibitor in patients with advanced sarcoma have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress being held in Paris, France, September 9 – 13, 2022 (Press release, NKMax America, SEP 6, 2022, View Source [SID1234619043]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation

Title: USFDA Authorized Compassionate Use of SNK01 (Autologous Non-Genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) and Checkpoint Inhibitors in Advanced Heavily Pre-treated Sarcoma: A Promising Regimen.
Poster #: P757
Date and Time: September 10, 2022, 10:38 am CEST
Poster Session: 13
Location: Paris Expo Porte de Versailles; Poster Area, Hall 4

Promising data aggregated from eight USFDA approved compassionate use IND cases from metastatic sarcoma patients who received SNK01 combined with a checkpoint inhibitor will be disclosed during the poster presentation. The combination of SNK01 and a checkpoint inhibitor appears to have clinical activity against several types of heavily pre-treated advanced sarcomas, independent of PD-L1 status. The data also suggests that repeated dosing with the combination appears to be safe and well-tolerated.

More information on the ESMO (Free ESMO Whitepaper) Congress 2022 can be found at the following link: View Source